Aquestive Therapeutics, Inc.
AQST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001398733
In the last 90 days, Aquestive Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 185 institutions reported holding it in 13F filings for Q2 2026, worth $299.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $373.5K in total
- 4
- 13F holdersQ2 2026, +6 vs. previous quarter
- 185
- 13F valueReported value at the end of Q2 2026
- $299.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AQST, Q2 2026
No superinvestor reported holding AQST at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Aquestive Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)2:00 PM ET | Sep 15 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.82 | −$120.5K | −3.7%652.3K after | 10b5-1 |
| Sep 11, 2026 (view filing)11:07 AM ET | Sep 9 | 2 days | Korczynski SherryChief Commercial Officer | SSale | −8.75K | $5.22 | −$45.7K | −3.6%235.7K after | 10b5-1 |
| Aug 18, 2026 (view filing)4:13 PM ET | Aug 17 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.29 | −$107.2K | −4.1%585.6K after | 10b5-1 |
| Jul 17, 2026 (view filing)1:15 PM ET | Jul 15-16 | 2 days | Barber DanielPresident and CEO | SSale | −25.0K | $4.01 | −$100.2K | −3.9%610.6K after | 2 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Krop JulieDirector | SSale | −25.0K | $5.02 | −$125.5K | −100.0%0 after | 10b5-1 |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Barber DanielPresident and CEO | SSale | −25.0K | $4.16 | −$104.0K | −3.8%635.6K after | 10b5-1 |
| May 18, 2026 (view filing) | May 15 | 3 days | Barber DanielPresident and CEO | SSale | −8.26K | $4.29 | −$35.4K | −1.2%660.6K after | 10b5-1 |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Boyd Peter E.Chief People Officer | SSale | −29.8K | $4.17 | −$124.3K | −8.1%338.5K after | |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Barber DanielPresident and CEO | SSale | −180.7K | $4.17 | −$753.4K | −15.2%1.00M after | |
| Mar 11, 2026 (view filing) | Mar 10 | 1 day | Braender Lori JChief Legal Officer | SSale | −40.1K | $4.17 | −$167.2K | −8.3%442.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Aquestive Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bratton Capital Management, L.P. | 9,810,958 | $40.8M | 100.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 8,069,373 | $33.6M | 0.00% | +560,302+7.5% | Added |
| RTW Investments, LP | 7,426,471 | $30.9M | 0.26% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,584,533 | $19.1M | 0.00% | +140,835+3.2% | Added |
| Federated Hermes, Inc. | 3,112,561 | $12.9M | 0.02% | +172,222+5.9% | Added |
| State Street Corp | 2,928,020 | $12.2M | 0.00% | +381,829+15.0% | Added |
| Geode Capital Management, LLC | 2,622,888 | $10.9M | 0.00% | +214,697+8.9% | Added |
| Samsara BioCapital, LLC | 2,500,000 | $10.4M | 0.85% | 00.0% | Unchanged |
| Bank of America Corp | 1,668,423 | $6.94M | 0.00% | −736,627−30.6% | Reduced |
| Sio Capital Management, LLC | 1,486,175 | $6.18M | 1.06% | −436,712−22.7% | Reduced |